failing human myocardium; thus other cAMP-independent mechanisms of action may be useful to increase force of contraction in this condition. The purpose of this investigation was to determine whether a positive inotropic effect of the cAMP-phosphodiesterase (PDE) inhibitor pimobendan is observed in the failing human myocardium and to study whether other factors, such as an increase in the Ca2+ sensitivity of myofilaments, play a functional role in the increase in force of contraction. Pimobendan produced a positiveinotropic effect in isolated preparations from nonfailing donor hearts; however, in moderately (New York Heart Association class TI-Ill, NYHA TI-ITT) and severely (NYHA IV) failing myocardium, this effect was reduced. In addition, in NYHA IV specimens pimobendan inhibited the crude cAMP-PDE (crude PDE) and the isoenzymesI-Ill (PDEI-IIT) in a concentration-dependent way. As judged from the IC50 values found in this tissue for the inhibition of PDE III and of crude PDE, the potency of the compound was 18.1 times greater on PDEIII. Consistent with a cAMP-PDE-dependent mechanism of action, the positive inotropic effect was potentiated byisoproterenol and inhibited by adenosine in failing myocardium. In failing myocardium, pimobendan also increased the sensitivity of skinned cardiac fibers to Ca2' and shifted the Ca2+-tension relation to the left. This sensitizing effect began at 0.01 ,moUl in NYHAIT-ITT and NYHA IV and rose to about 200%o at 300 ,umol/l in both groups. In contrast, the demethylated metabolite UD-CG 212 Cl failed to produce positive inotropic effects in failing myocardium alone, but in the presence of isoproterenol, it exerted an increase in force of contraction. The potency of UD-CG 212 Cl for PDE Ill inhibition in NYHA IV was greater than that of pimobendan. The metabolite pronouncedly decreased the sensitivity of skinned cardiac fibers to Ca2' at 30-300 ,umolI1 in NYHA IT-ITT and NYHA IV. It is concluded that in the failing human heart pimobendan inhibited PDE ITT and sensitized contractile proteins for Ca2+. Both effects appear to be involved in the positive inotropic effect of the compound, because its metabolite, UD-CG 212 Cl, had no effect on force of contraction and on the Ca21 sensitivity of skinned cardiac fibers but inhibited PDE ITT even more potently than pimobendan.
IV was greater than that of pimobendan. The metabolite pronouncedly decreased the sensitivity of skinned cardiac fibers to Ca2' at ,umolI1 in NYHA IT-ITT and NYHA IV. It is concluded that in the failing human heart pimobendan inhibited PDE ITT and sensitized contractile proteins for Ca2+. Both effects appear to be involved in the positive inotropic effect of the compound, because its metabolite, UD-CG 212 Cl, had no effect on force of contraction and on the Ca21 sensitivity of skinned cardiac fibers but inhibited PDE ITT even more potently than pimobendan.
These findings suggest that PDE inhibition alone by the benzimidazole derivatives might not be sufficient to increase force of contraction in the failing human heart, indicating that an additional mechanism, such as a Ca2+-sensitizing effect of pimobendan, may have functional relevance.
(Circulation Research 1991; 68:689-701) I n recent years, positive inotropic compounds have failure.1 Pimobendan (UD-CG 115 BS) is reported to been developed as alternative drugs to cardiac inhibit cAMP-phosphodiesterases (PDEs),2-4 to proglycosides in the treatment of chronic heart Supported by the Deutsche Forschungsgemeinschaft. long the action potential duration,5 and to sensitize guinea pig and dog myofilaments to Ca2+.6-8However, it is unclear whether both cAMP-PDE inhibition and Ca2' sensitization or only one of these mechanisms is causally related to the positive inotropic effect of the compound. Only few data on the positive inotropic effects of pimobendan in failing human myocardium and on the mechanisms involved are available.9 These questions are of importance, since in the failing myocardium the positive inotropic response to PDE inhibitors is reported to be impaired. [10] [11] [12] The reduced mechanical responses to these agents have been suggested to be due to a reduced basal cAMP formation in the failing heart.1013,14 An increase in sensitivity of the myofilaments to Ca2' might be useful to lower the energy expenditure for the failing heart while increasing force of contraction.15 Moreover, it is not unreasonable to assume that these agents could produce positive inotropism at lower Ca2' concentrations in the myocardial cell than those agents with cAMPincreasing properties alone.16 It was the aim of this investigation to characterize the positive inotropic effect of pimobendan in human failing myocardium and to study whether both inhibition of cAMP-PDE and sensitization of the contractile proteins are involved. Therefore, the effects on force of contraction of pimobendan were studied in isolated, electrically driven preparations from human hearts of patients with variable degrees of heart failure (nonfailing, New York Heart Association class II-III [NYHA 11-1111, and NYHA IV) and compared with the inotropic responses to isoproterenol and to an elevation of the extracellular Ca2' concentration. In failing myocardium, the effects on the activity of the crude cAMP-PDE, the PDE isoenzymes I-III, and the Ca2'-tension relation of skinned cardiac fibers were also studied and compared with the effects of the demethylated main metabolite UD-CG 212 Cl.
Materials and Methods Myocardial Tissue
All experiments were performed on preparations from human papillary muscles or on isolated, electrically stimulated, human papillary muscle strips. through a sterile filter unit (MILLEX-GS 0.22 gm, Millipore Corp., Bedford, Mass.) and 2 ml of this filtered supernatant was injected into an FPLC system LCC 500 (Pharmacia-LKB) equipped with a prepacked 5 -ml Mono-Q anionic exchange column (HR 5/5, Pharmacia-LKB). The separation of the PDE isoenzymes was performed with a nonlinear gradient of NaCl concentration (0-1 mol/l); flow rate was 1 ml/min and maximal pressure was 1.5-2.5 MPa. Fractions of 1 ml were collected, and the cAMP-PDE and cGMP-PDE activities were measured with a substrate concentration of 1.0 ,mol/l cAMP or 0.1 gmol/l cGMP, respectively. Three peaks of PDE activity could be identified and pooled as PDE I, PDE II, and PDE III. The activity pattern of the PDE isoenzymes separated by this FPLC method was similar to those described previously. 19 Determination of phosphodiesterase activity. Inhibition of high-affinity cAMP-and cGMP-PDE in the crude enzymes as well as in PDE I, PDE II, and PDE III isoenzyme preparations of human left ventricles was determined by a modified radioisotope method as described by van Table 2 ). Again, the effect of Ca21 was not different in either group or under either condition tested. To study whether the positive inotropic effect of pimobendan is involved in cAMP elevation, the effect of a high concentration of adenosine in the presence of pimobendan was studied in NYHA II-III. In Figure 5A , an original recording illustrates the effect. After equilibration of the positive inotropic effect of pimobendan, 1,000 gmol/l adenosine was applied.
Note that a negative inotropic effect of adenosine, peaking at 3 minutes, was observed in the presence of pimobendan. Figure 5B summarizes more potent than the inhibition of crude PDE. UD-CG 212'Cl was 7.7 times more potent at PDE III than pimobendan was. The IC50 values for inhibition of PDE I-III are included in Figure 6 .
Ca2' Sensitivity of the Myofibrils Figure 7 shows the effect of pimobendan on the Ca2'-tension relation of a skinned fiber from a heart of a patient with terminal heart failure (NYHA IV).
Note that the increase in tension at higher pCa values was more pronounced in the presence of pimobendan than without. Figure 7B summarizes the concentration-response curves. There was a significant shift of 0.15 pCa units to the left by the addition of 100 ,umol/l pimobendan. Figure 8 shows the data for UD-CG 212 Cl. In the presence of UD-CG 212 Cl, the increase in tension was reduced at low pCa values ( Figure 8A ), and the concentration-response curve was shifted to the right ( Figure 8B ), indicating a decrease in the sensitivity of the contractile proteins for Ca2 . Concontration of UD-CG 212 CL (pmol/I) Pimobendan increased the duration of isometric single contractions not only in human (this study) but also in guinea pig2 and ferret34 papillary muscles. Moreover, pimobendan more pronouncedly increased force of contraction in relation to the positive chronotropic effect compared with isoproterenol.2 To study whether sensitization to Ca21 of the contractile proteins plays a role, we studied the effect of pimobendan on Ca2+-force relations of skinned fibers from failing hearts. Pimobendan increased the Ca21 sensitivity of myocardial skinned fibers from the hearts of patients with moderate and severe heart failure. Similar effects have previously been observed in guinea pig6-8 and dog7 myocardium. Therefore, it is reasonable to assume that this mechanism contributes to the positive inotropic response in failing human heart muscle.
The demethylated major metabolite of pimobendan, UD-CG 212 Cl, has been shown to inhibit cAMP-PDE2 and to increase force of contraction in guinea pig myocardium even more potently than the parent compound, pimobendan.2 Moreover, UD-CG 212 Cl reduced left ventricular end-diastolic pressure and vascular resistance in anesthesized pigS.35 In the failing myocardium, it inhibited PDE III 7.7 times more potently than pimobendan did (this study). When the preparations were preincubated with isoproterenol, UD-CG 212 Cl produced a positive inotropic effect. As judged from the EC50 values, UD-CG 212 Cl was even more potent than pimobendan in increasing force of contraction under these conditions. These findings indicate that although there was no positive inotropic effect with UD-CG 212 Cl alone in the failing myocardium, PDE inhibition might be involved in the positive inotropic effect in the presence of isoproterenol in failing myocardium. Similar results were obtained with the PDE III inhibitor milrinone,10 which has no effect on Ca>2 sensitivity of the myofibrils.7 In one study on preparations from severely failing hearts, milrinone as UD-CG 212 Cl (this study) failed to increase force of contraction alone, but a marked response to the PDE inhibitor was observed in the presence of the adenylate cyclase stimulator forskolin.10 The positive inotropic effect of pimobendan and the failure of its metabolite UD-CG 212 Cl to increase force of contraction indicates that an additional mechanism of action is involved in the effect of the parent compound. The desensitizing properties of UD-CG 212 Cl at high concentrations could also contribute to the lack of effect of the metabolite. The data on UD-CG 212 Cl alone show that even strong PDE III inhibition is not capable of producing positive inotropic effects. The results with the metabolite in the presence of isoproterenol suggest that the maximal effect on force of contraction at 10 ,umol/l is observed only when PDE III is inhibited by 77% of basal activity.
The data of this study provide evidence that PDE inhibition and sensitization of the contractile proteins to Ca' both acting in concert are causally related to the positive inotropic effect of pimobendan. As pointed out by Lee et al,34 a combined action of cAMP-PDE inhibition and Ca' sensitization could have comparative advantages over mechanisms involving only one of these effects. This must be anticipated since an increased binding of Ca' to troponin C initiated by its increased affinity for Ca> relies on the intracellular concentration of free Ca> achieved by a cAMP-dependent increase of the slow Ca> inward current or on the cAMP-dependent phospholamban phosphorylation. Therefore, in patients with heart failure in which a permanent 83-adrenergic stimulus is imposed on the heart by activation of the sympathetic nervous system36 and elevated norepinephrine levels,37-39 beneficial hemodynamic effects caused by direct inotropic effects on the failing heart by pimobendan are nevertheless possible.
